Apotex Expands U.S. Portfolio via Cumberland Deal
TORONTO, April 23, 2026 Apotex Inc. and Cumberland Pharmaceuticals Inc. announced a strategic transaction to integrate Cumberland’s U.S. branded...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
TORONTO, April 23, 2026 Apotex Inc. and Cumberland Pharmaceuticals Inc. announced a strategic transaction to integrate Cumberland’s U.S. branded...
